June Spotlight: Expanding Access to Pediatric Cancer Treatments Through Pediatric Study Plans
Written by: Diya Sriramagiri
Each year, thousands of children are diagnosed with cancer, yet many new cancer therapies are initially developed and tested only in adults. This delay can leave pediatric patients waiting years for access to promising treatments that may already be showing success in adult populations. To address this gap, regulatory agencies such as the U.S. Food and Drug Administration (FDA) have strengthened requirements for Pediatric Study Plans (PSPs), which encourage drug developers to consider pediatric testing much earlier in the development process.
A Pediatric Study Plan is a framework that outlines how a pharmaceutical company will evaluate a new drug in children. Rather than waiting until adult trials are complete, companies are often required to submit pediatric development plans during the early stages of drug development. This approach helps identify opportunities for pediatric testing sooner, particularly for cancer therapies that target biological pathways shared between adult and childhood cancers.
The impact of Pediatric Study Plans extends beyond research timelines. Earlier pediatric evaluation can increase access to innovative treatments, accelerate the development of child-specific dosing and safety information, and expand clinical trial opportunities for pediatric patients. For families facing childhood cancer, timely access to novel therapies can be critical, especially when standard treatments are limited or ineffective.
From a health equity perspective, policies that promote pediatric inclusion in clinical research help ensure that children are not overlooked in the development of lifesaving treatments. While challenges such as geographic barriers, transportation, and clinical trial availability still affect access for many families, Pediatric Study Plans represent an important step toward creating a more equitable system where children can benefit from scientific advances alongside adults.
As Project 46 continues exploring disparities in pediatric cancer care, initiatives like Pediatric Study Plans highlight how policy can play a powerful role in improving outcomes for children and expanding access to innovative treatments. By prioritizing pediatric research earlier in the drug development process, healthcare systems can move closer to ensuring that every child has the opportunity to benefit from the latest breakthroughs in cancer care.
Works Cited
C S, Chinmayi, et al. “An Overview and Comparison of Regulatory Pathways and Guidelines for Pediatric Study Plans in the US and EU.” Journal of Medicinal and Chemical Sciences, vol. 6, no. 12, 1 Dec. 2023, pp. 3057–3071, www.jmchemsci.com/article_177331.html, https://doi.org/10.26655/JMCHEMSCI.2023.12.21.
Research, Center for Drug Evaluation and. “Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans.” U.S. Food and Drug Administration, 30 July 2020, www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-study-pla ns-content-and-process-submitting-initial-pediatric-study-plans-and-amended
